SynthesisVirology journal2016
Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis.
Synthesis in Virology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination.Clinical and experimental nephrology · 2020Trial
- The impact of variations in the chikungunya genome on the clinical manifestations and transmission of the disease.Journal of family medicine and primary care · 2025Review
- Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir.Scientific reports · 2025Article
- Recent Advances in Hepatitis B Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection.Medicine · 2020Article
- Association between serum Cystatin C and renal injury in patients with chronic hepatitis B.Medicine · 2020Article
- Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy.Medicine · 2020Observational
- Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma.The Journal of international medical research · 2020Article
- Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma.Oncology letters · 2019Article
- Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan.Experimental and therapeutic medicine · 2019Article
- Current perspectives into the evaluation and management of hepatitis B: a review.Hepatobiliary surgery and nutrition · 2019Review
- Dynamic change of depression and anxiety after chemotherapy among patients with ovarian cancer.Medicine · 2019Observational
- How to estimate renal function in patients with liver disease: choosing the most suitable equation.International urology and nephrology · 2019Article
- Health related quality of life in stroke patients and risk factors associated with patients for return to work.Medicine · 2019Article
- Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy.Medicine · 2019Observational
- Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma.Infectious agents and cancer · 2019Article
- Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B.Infection and drug resistance · 2019Article
- Risk factors associated with fatigue in chronic hepatitis B patients.Patient preference and adherence · 2019Article
- Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy.Pharmacogenomics and personalized medicine · 2019Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the potential effects of telbivudine (LdT) and entecavir (ETV) on renal function in patients with chronic hepatitis B (CHB), we performed a meta-analysis of the relevant data available on these agents to evaluate their effects on the estimated glomerular filtration rate (eGFR) during treatment.
methodsThe PubMed, EMBASE, Scopus, CNKI (China National Knowledge Infrastructure), Cochrane Library, and WanFang databases were searched for relevant articles appearing in the literature up to July 1, 2015. A total of 6 studies (1960 CHB patients) with 1-year eGFR outcomes were retrieved and analyzed.
resultsGenerally, the results of the 6 studies analyzed showed that eGFR was improved after LdT treatment, but was decreased after ETV treatment. Using a fixed-effects approach, the change in eGFR was found to be significantly different between LdT and ETV treatment (Z = 3.64; P = 0.0003). Whereas the eGFR was slightly decreased with ETV compared with baseline (-1.45 mL/min/1.73 m(2)), the eGFR was improved with LdT (2.99 mL/min/1.73 m(2)) after 1 year of treatment. An overall test of effect in the meta-analysis showed that the eGFR in LdT-treated patients was significantly improved after 1-year of treatment (Z = 3.71; P = 0.0002).
conclusionThis meta-analysis has confirmed that LdT has a renal protective effect whereas ETV does not. However, whether the benefit on renal function outweighs the occurrence of resistance in specific clinical situations is not yet clear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.